03:01:12 EDT Mon 27 May 2024
Enter Symbol
or Name

Login ID:
Innocan Pharma Corp
Symbol INNO
Shares Issued 248,490,093
Close 2023-03-10 C$ 0.25
Market Cap C$ 62,122,523
Recent Sedar Documents

Innocan receives U.S. patent notice of allowance

2023-03-13 01:20 ET - News Release

Ms. Iris Bincovich reports


The U.S. Patent and Trademark Office has issued a notice of allowance for Innocan Pharma Corp.'s patent application No. 16/968,627 with claims related to the company's combined cannabis and magnesium topical pain relief technology.

The patent discloses and claims breakthrough magnesium and cannabis-based technology that is administered topically. The technology is designed to systemically relieve pain and/or itching, and is administered by spray, roll-on or lotion.

The company intends to file further patent applications with the USPTO, as well as with other patent offices worldwide, to further establish its novel cannabis-based intellectual property portfolio.

Innocan's chief executive officer, Iris Bincovich, stated: "We are glad to see a robust and vivid indication of our pain relief technology, adding to Innocan's intellectual property portfolio. Receiving the patent approval from the USPTO will assist us in our commercialization efforts."

About Innocan Pharma Corp.

Innocan is a pharmaceutical technology company that operates under two main segments: pharmaceuticals and consumer wellness. In the pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies with cannabinoid science to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) The LPT cannabidiol-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the bloodstream. The LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management. (ii) The CLX cannabidiol-loaded exosome platform that may hold the potential to provide a highly synergistic effect of regenerating and anti-inflammatory properties targeting the central nervous system (CNS). In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative and high performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on developing advanced targeted on-line sales.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.